Compare AbbVie Inc (ABBV) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Target Corporation — how do they compare? AbbVie Inc trades at $252.67 (market cap $439.59B), while Target Corporation trades at $154.71 (market cap $69.95B). The key difference: AbbVie Inc is far larger — about 6.3× Target Corporation's market cap, and Target Corporation pays the higher dividend (3.01%). Which is the better fit depends on your goals.
| ABBV | TGT | |
|---|---|---|
Market Cap | $439.59B | $69.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $154.02 |
52-Week Low | $197.38 | $83.68 |
Enterprise Value | $503.84B | $85.24B |
Dividend Yield | 2.78% | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $251.70, up 0.7% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $278.69. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $3.87. Revenue growth is robust, driven by immunology drugs Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Recent news highlights positive Phase 2 trial data for ELAHERE in ovarian cancer and institutional buying interest.
AbbVie's outlook is positive with strong revenue growth and a high analyst buy rating (70.73%), but risks include patent expirations in the 2030s, elevated debt levels, and margin pressure. The stock offers a compelling dividend and growth profile, though investors must monitor competitive and regulatory challenges.
Target Corporation (TGT) trades at $153.50, up 0.93% today, with strong technical momentum and bullish moving averages. Recent earnings beats and the appointment of a Chief AI Officer highlight operational strength. The stock is near its 52-week high, supported by positive analyst sentiment and consistent dividend payments.
Outlook remains positive with solid fundamentals and growth initiatives, though overbought technical indicators and competitive retail pressures pose risks. Revenue stability and margin improvements are key drivers, but investor caution is warranted near resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
